TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean change in low-luminance best-corrected visual acuity (ll-BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in size of geographic atrophy (GA) on fundus autofluorescence (FAF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with myocardial injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient-reported voice VAS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With One or More Treatment-Emergent Adverse Event(s)
Endpoint domain: Adverse events/effects
Primary endpoint: Weaning rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of unprotected vaginal or anal sex
Endpoint domain: Adverse events/effects
Primary endpoint: Sustained MRD-negative CR
Endpoint domain: Mortality/survival
Primary endpoint: Tool-in-lesion positioning accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean levels of new blood biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Patient-reported adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Clinical Disease Activity Index (CDAI) <=10.0
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Dystrophin Protein Levels in Muscle Tissue at Week 25
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exclusive Breastfeeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Hypercortisolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pulmonary immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of ocular treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically significant change in blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accuracy on a two-choice paired associate test immediately after the task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Accuracy on a two-choice paired associate test 1 week after the task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Complete Response at 30 months (CR30)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder Isometric Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days to Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in UTI episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) of cabotegravir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration - time curve from time zero to 4 weeks following the injection (AUC[0-4]) of cabotegravir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with adverse events (AEs) based on severity
Endpoint domain: Adverse events/effects
Primary endpoint: Human Papilloma Virus infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Hepatitis B immunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: cancer of cervix
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cancer of the liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of mortality within 6 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Total cholesterol in mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LDL-cholesterol in mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Triglycerides in mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Technical success of the surgical intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Predictors of limb salvage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Cardiac Rehabilitation attendance rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of patients with very good partial response (VGPR) or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with reduced initially upregulated oncogenic proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of subjects experiencing a DLT
Endpoint domain: Adverse events/effects
Primary endpoint: Rosenbek penetration-aspiration scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysmenorrhea Induced Pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 6-Min Walk Test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Voluntary Muscle Strength Tests (Isokinetics)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Voluntary Muscle Strength Tests (Isometrics)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Evoked Muscle Function Assessments: Evoked Peak Force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Evoked Muscle Function Assessments: Evoked Peak Rate of Force Development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Rate of Muscle Activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with grade 3 or higher adverse events during study drug treatment
Endpoint domain: Adverse events/effects
Primary endpoint: TB disease-free survival at six months post randomization
Endpoint domain: Mortality/survival
Primary endpoint: Time to stable sputum culture conversion on solid and liquid media
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of participants with safety event
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients by initial dose of ribociclib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients by endocrine therapy partner
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of patients for each line of treatment with ribociclib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease of Depression Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Complete Metabolic Response (CMR) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PAPP-A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: PGLF (Placenta growth factor)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: S-FLT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: AFP (alpha fetal protein)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time to confirmation of bilateral ureteral patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: change of pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of participants functionality
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: participants satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Imaging integration success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Weight loss attempts in past year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of follow-up appointments made to discuss obesity
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Assessment of interactions between adolescents living with obesity and healthcare providers
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Developmental assessment using Battelle Development Inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hetero-evaluation using the IES-R scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-report using the STAI inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: proportion of preeclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: change in sleeping quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: change in the quality of life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Schirmer Test Mean Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Low Density Lipoprotein cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients achieving at least 30% reduction of the NRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impressions Improvement scale (clinician)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical Global Impressions Improvement scale (caregiver)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Visual Analog scale (patient caregiver)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in auditory response to chirp stimulus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of adult subjects with absence of hematologic relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Behavioral peer interaction measurement
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Insightfulness Assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Heart Failure with Reduced Ejection Fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in Ichthyosis Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Occurrence of bacterial and fungal infections
Endpoint domain: Adverse events/effects
Primary endpoint: Concordance of Illness Perceptions Questionnaire Change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: System Evaluation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of invasive pneumococcal disease
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of all cause pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Change in SIGH-A Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of TEAEs and TESAEs
Endpoint domain: Adverse events/effects
Primary endpoint: short-term neurological outcome prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients remaining on asciminib at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Adherence to ESMO 2018 Guidelines
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Participant With Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Weaning success/failure from mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of patients with new stroke event
Endpoint domain: Mortality/survival
Primary endpoint: Change in Pelvic Floor Disability Index (PFDI-20)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in pelvic floor impact questionnaire (PFIQ-7)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients demonstrating NEDA-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of renal dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of COVID-19 infection
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants achieving complete response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute change in CAPS-5-R total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of new or worsening suicidal thoughts or behaviors
Endpoint domain: Adverse events/effects
Primary endpoint: CGM Dynamic Index (CDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pharmacokinetic profile of rifabutin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stimulation amplitude threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Clinically Significant Change From Baseline in Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Clinically Significant Change from Baseline in Clinical Laboratory Test Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in IIEF-EF Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants achieving MCID in IIEF-EF
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Penile Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CNS-specific progression-free survival (PFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal plasma glucose values at 0-hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maternal plasma glucose values at 1-hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maternal plasma glucose values at 2-hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of respiratory tract infections (RTIs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: BrainHealth Index Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Lines of improvement of monocular UCVA at the 12-month visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of eyes achieved UCVA of ≤0.30 logMAR, ≤0.20 logMAR, ≤0.10 logMAR, and ≤0.00 logMAR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and rates of serious and significant adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in neuropathic pain intensity or unpleasantness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in brain electrocortical activity at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time-to-crisis resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in MDS E0200 pre/post intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in MDS E0800 pre/post intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in MDS E1100 pre/post intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in MDS N0410 pre/post intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in NHQM Prescribed Antipsychotic pre/post intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Survey 757 and 758 Noncompliance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: marginal bone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forced expiratory volume in one second/forced vital capacity ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Heavy Episodic Drinking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Modal alcohol consumption
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Muscle Sympathetic Nerve Burst Incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Muscle Sympathetic Nerve Burst Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Muscle Sympathetic Nerve Burst Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in chronic neuropathy symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Active range of motion mobility in the inferior cervical region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Active range of motion mobility in the upper cervical region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants to Complete Two PET scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants to Complete Cognitive Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Diagnostic performance of Xpert Ultra
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analog scale (VAS) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Safety (adverse events, serious adverse events, adverse drug reactions)
Endpoint domain: Adverse events/effects
Primary endpoint: Implementation of survivorship care recommendations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants with treatment emergent adverse event (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with treatment emergent adverse event (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Identification of AF participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Change in Wellness
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Plasma Periostin Levels and Degree of Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug-related adverse event rate
Endpoint domain: Adverse events/effects
Primary endpoint: Change in level of Physical Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of subjects achieving biochemical response in IGF-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Comparison of advanced airway methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Children's Fear Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Childhood Anxiety Meter Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: number of polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Infant Motor Development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Infant Developmental Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Parental Play Behaviors: Positioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Speed of endoscopic submucosal dissection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Post Operative Staple Line Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline to Week 52 in the PSPRS Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nine Hole Peg Test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment response of anti-cancer therapy at first evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Quality of life (mental health)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Quality of life (physical health)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Hypoglycemic events defined as glucose values below 3.0 mmol/l
Endpoint domain: Adverse events/effects